DFE Pharma opens Centre of Excellence in India to provide fast-track formulation services

DFE Pharma recently announced the launch of its new Centre of Excellence “Closer to the Formulator” (C2F) in Hyderabad, India. The C2F centre is based in Genome Valley, a hub of major Indian and global (bio)pharma companies and renowned research organisations. C2F helps pharma companies to shorten the time from a concept to a finished commercial product through expertise in all phases of pharma development, a company statement notified.

The services offered by the new facility are focussed on oral solid dosage forms, comprising all types of pre-registration work, including development, scale-up and technology transfer. Formulation support includes specialised dosage forms such as orally disintegrating, effervescent, chewable and sub-lingual tablets, minitablets, etc. C2F capabilities also support efficiency projects such as conversion from wet granulation to direct compression, the statement said.

The centre works with the Active Pharmaceutical ingredients (APIs) and can utilise innovative concepts with model APIs. The equipment covers an instrumented tablet press, an automated capsule filling machine, a tablet coater, a blister packaging machine, stability chambers and analytical equipment. The C2F offering can provide pharma companies with multiple advantages such as significantly lowering the number of development cycles, for example, and reducing formulation costs when launching a medicine.

Speaking on the occasion, KT Rama Rao, Cabinet Minister for IT, Industries and Commerce, Municipal Administration and Urban Departments, Telangana, said in the statement, “I’m delighted to welcome DFE Pharma, a global leader in pharma and nutraceutical excipient solutions in Genome Valley, Hyderabad. We are happy to support and facilitate the establishment of “Closer to the Formulator” (C2F) with the major objective of helping pharma companies to move up the value chain. The government of Telangana will work with DFE Pharma to ensure that lifesciences companies in the state leverage from this facility.”

Speaking about C2F, Martti Hedman, CEO, DFE Pharma, added in the statement, “DFE Pharma has made a multi-million-euro investment in the new Centre of Excellence in Hyderabad. Our overall goal is to help the global and Indian pharmaceutical industry to launch new products fast, at a low cost, and always first-time-right. This new Center of Excellence demonstrates how DFE Pharma anticipates trends and innovations to increase patient’s access to safe, high-quality medicines.”

In addition to it, Dr Anilkumar S Gandhi, Director, C2F centre, also noted in the statement, “……..Our services result in robust formulations, utilising top-level excipient expertise transferrable to scale-up. We aim to further collaborate with our customers in this new centre to combine the joint formulation expertise.”